In an in vitro study, the potential of gedunin alone or with epalrestat (AR inhibitor) to prevent hallmarks of cancer by inhibiting the downstream PI3K/Akt/mTOR/ERK/NF-κB signalling axis and aldose reductase (AR) in the oral cancer cell line SCC131 was examined. The gene discussed is AR; the disease is lip and oral cavity carcinoma.